首页 > 科学研究 > 科研进展 > A Convergence-Based Framework for Cancer Drug Resistance.
A Convergence-Based Framework for Cancer Drug Resistance.
来源:Cancer Cell. 2018 May 14;33(5):801-815.   作者:Konieczkowski DJ, Johannessen CM, Garraway LA.   发布时间:2018/5/24 18:10:58

Despite advances in cancer biology and therapeutics, drug resistance remains problematic. Resistance is often multifactorial, heterogeneous, and prone to undersampling. Nonetheless, many individual mechanisms of targeted therapy resistance may coalesce into a smaller number of convergences, including pathway reactivation (downstream re-engagement of original effectors), pathway bypass (recruitment of a parallel pathway converging on the same downstream output), and pathway indifference (development of a cellular state independent of the initial therapeutic target). Similar convergences may also underpin immunotherapy resistance. Such parsimonious, convergence-based frameworks may help explain resistance across tumor types and therapeutic categories and may also suggest strategies to overcome it.

 

 

 

Doi: 10.1016/j.ccell.2018.03.025.

 

版权所有:济宁医学院精准医学研究院  地址:济宁市北湖新区荷花路16号科研楼三楼  邮编:272067